EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

BA.1, BA.2 and BA.2.75 variants show comparable replication kinetics, reduced impact on epithelial barrier and elicit cross-neutralizing antibodies

Janmejay Singh, Anbalagan Anantharaj, Aleksha Panwar, Chitra Rani, Monika Bhardwaj, Parveen Kumar, Partha Chattopadhyay, Priti Devi, Ranjeet Maurya, Pallavi Mishra, Anil Kumar Pandey, Rajesh Pandey und 1 weitere

PLOS Pathogens · 2023

DOI: 10.1371/journal.ppat.1011196 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Pathogens, 2023. Verfasst von Janmejay Singh und 12 weiteren Autor:innen. Beteiligte Einrichtung: Bioassay Laboratory and Clinical and Cellular Virology Laboratory, Translational Health Science and Technology Institute, Faridabad, Haryana, India. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Biotechnology, Ministry of Science and Technology, India, Indo-US Science and Technology Forum, Bill and Melinda Gates Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Omicron variant of SARS-CoV-2 is capable of infecting unvaccinated, vaccinated and previously-infected individuals due to its ability to evade neutralization by antibodies. With multiple sub-lineages of Omicron emerging in the last 12 months, there is inadequate information on the quantitative antibody response generated upon natural infection with Omicron variant and whether these antibodies offer cross-protection against other sub-lineages of Omicron variant. In this study, we characterized the growth kinetics of Kappa, Delta and Omicron variants of SARS-CoV-2 in Calu-3 cells. Relatively higher amounts infectious virus titers, cytopathic effect and disruption of epithelial barrier functions was observed with Delta variant whereas infection with Omicron sub-lineages led to a more robust induction of interferon pathway, lower level of virus replication and mild effect on epithelial barrier. The replication kinetics of BA.1, BA.2 and BA.2.75 sub-lineages of the Omicron variant were comparable in cell culture and natural infection in a subset of individuals led to a significant increase in binding and neutralizing antibodies to the Delta variant and all the three sub-lineages of Omicron but the level of neutralizing antibodies were lowest against the BA.2.75 variant. Finally, we show that Cu 2+ , Zn 2+ and Fe 2+ salts inhibited in vitro RdRp activity but only Cu 2+ and Fe 2+ inhibited both the Delta and Omicron variants in cell culture. Thus, our results suggest that high levels of interferons induced upon infection with Omicron variant may counter virus replication and spread. Waning neutralizing antibody titers rendered subjects susceptible to infection by Omicron variants and natural Omicron infection elicits neutralizing antibodies that can cross-react with other sub-lineages of Omicron and other variants of concern.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19HumansBroadly Neutralizing AntibodiesKineticsSARS-CoV-2Antibodies, NeutralizingInterferonsAntibodies, Viral

Substanzen

Broadly Neutralizing AntibodiesAntibodies, NeutralizingInterferonsAntibodies, Viral

Autor:innen und Institutionen

  • Bioassay Laboratory and Clinical and Cellular Virology Laboratory, Translational Health Science and Technology Institute, Faridabad, Haryana, India.
  • INtegrative GENomics of HOst-PathogEn (INGEN-HOPE) laboratory, CSIR-Institute of Genomics and Integrative Biology, Delhi, India.
  • Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India.
  • Employees State Insurance Corporation Medical College and Hospital, Faridabad, Haryana, India.

ORCID-Profile: Guruprasad R Medigeshi

Förderung

  • Department of Biotechnology, Ministry of Science and Technology, India
  • Indo-US Science and Technology Forum
  • Bill and Melinda Gates Foundation

Zitieren

APA

Singh, J., Anantharaj, A., Panwar, A., Rani, C., Bhardwaj, M., Kumar, P., Chattopadhyay, P., Devi, P., Maurya, R., Mishra, P., Pandey, A. K., Pandey, R., & Medigeshi, G. R. (2023). BA.1, BA.2 and BA.2.75 variants show comparable replication kinetics, reduced impact on epithelial barrier and elicit cross-neutralizing antibodies. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1011196

Vancouver

Singh J, Anantharaj A, Panwar A, Rani C, Bhardwaj M, Kumar P, et al. BA.1, BA.2 and BA.2.75 variants show comparable replication kinetics, reduced impact on epithelial barrier and elicit cross-neutralizing antibodies. PLOS Pathogens. 2023. doi:10.1371/journal.ppat.1011196

BibTeX
@article{Singh2023,
  author = {Singh, Janmejay and Anantharaj, Anbalagan and Panwar, Aleksha and Rani, Chitra and Bhardwaj, Monika and Kumar, Parveen and Chattopadhyay, Partha and Devi, Priti and Maurya, Ranjeet and Mishra, Pallavi and Pandey, Anil Kumar and Pandey, Rajesh and Medigeshi, Guruprasad R},
  title = {BA.1, BA.2 and BA.2.75 variants show comparable replication kinetics, reduced impact on epithelial barrier and elicit cross-neutralizing antibodies},
  journal = {PLOS Pathogens},
  year = {2023},
  doi = {10.1371/journal.ppat.1011196}
}
Kostenlos starten →